Form 4: Viridian Therapeutics Director Jennifer K. Moses Granted Stock Options
SEC Form 4 Filing
Director Jennifer K. Moses acquired 21,000 stock options in Viridian Therapeutics, Inc. on June 26, 2024, vesting in full by June 26, 2025, or the 2025 annual meeting.
Summary
- Jennifer K. Moses, a director of Viridian Therapeutics, Inc., was granted 21,000 stock options on June 26, 2024.
- The exercise price of these options is $12.31 per share.
- The options vest in full upon the earlier of June 26, 2025, or the Issuer's 2025 annual meeting of stockholders, contingent upon continued service on the Board.
- The options expire on June 26, 2034.
- Following the transaction, Ms. Moses directly owns 21,000 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive as it reflects standard compensation practices and aligns director interests with shareholders. There are no indications of negative events or concerns.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders.
- The vesting schedule incentivizes continued service on the board.
Future Outlook
The director's holdings and transactions will continue to be reported via Form 4 filings as required by the Securities Exchange Act of 1934.
Industry Context
Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology sector, to incentivize performance and align interests with shareholders.
Comparison to Industry Standards
- Stock option grants to directors are a standard practice across the biotechnology industry.
- Companies like Amgen, Regeneron, and Gilead Sciences also utilize stock options as part of their compensation packages for board members.
- The vesting schedules and exercise prices are typically structured to align with long-term value creation for shareholders.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of the shareholders, incentivizing value creation.
- The grant has no immediate impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 06/26/2024 | Date of the stock option grant and transaction. |
| 06/26/2025 | Earliest vesting date for the stock options. |
| 06/26/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.